Showing results (231-240 of 245) with videos related to

Sort By:
Pageof 25
ESMO Open|July 30, 2026
Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing biliary tract or pancreatic tumors: a subgroup analysis of DESTINY-PanTumor02D-Y Oh, I Ługowska, D Stroyakovskiy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 21, 2019
Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trialS T Kim, J H Kang, J Lee, et al.
European Journal of Neurology|August 13, 2015
Impact of smoking on neurodegeneration and cerebrovascular disease markers in cognitively normal menH Cho, C Kim, H J Kim, et al.
British Journal of Cancer|October 28, 2015
A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancerS H Lim, T W Kim, Y S Hong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 25, 2014
A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancerS H Lim, J Y Lee, M-Y Lee, et al.
European Journal of Neurology|July 5, 2014
Higher C-peptide levels are associated with regional cortical thinning in 1093 cognitively normal subjectsC W Yoon, M Kang, H Y Shin, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 28, 2023
Pneumonitis After Concurrent Chemoradiation and Immune Checkpoint Inhibition in Patients with Locally Advanced Non-small Cell Lung CancerM Altan, F Soto, T Xu, et al.
Oncogene|December 6, 2011
Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancerW Liu, J Lindberg, G Sui, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 5, 2020
A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial☆S H Park, D H Lim, T S Sohn, et al.
ESMO Open|August 27, 2022
Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort AD V T Catenacci, Y-K Kang, H H Yoon, et al.
Pageof 25